DRASC

Serial Number 88096818
602

Registration Progress

Application Filed
Aug 29, 2018
Under Examination
Apr 16, 2019
Approved for Publication
Feb 19, 2019
Published for Opposition
Feb 19, 2019
Registered

Trademark Image

DRASC

Basic Information

Serial Number
88096818
Filing Date
August 29, 2018
Published for Opposition
February 19, 2019
Abandonment Date
February 4, 2021
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Feb 16, 2021
Classes
042 044

Rights Holder

AccuBeing, LLC

16
Address
202 Pebble Springs Road
Chapel Hill, NC 27514

Ownership History

AccuBeing, LLC

Original Applicant
16
Chapel Hill, NC

AccuBeing, LLC

Owner at Publication
16
Chapel Hill, NC

Legal Representation

Attorney
Devon E. White

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

34 events
Date Code Type Description Documents
Feb 16, 2021 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Feb 16, 2021 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Aug 3, 2020 CNFR W SU - FINAL REFUSAL - WRITTEN Loading...
Aug 3, 2020 GNFR O FINAL REFUSAL E-MAILED Loading...
Aug 3, 2020 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Jul 29, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 28, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 28, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 28, 2020 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Apr 28, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Apr 28, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 9, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 9, 2020 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 24, 2020 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Mar 24, 2020 IUAF S USE AMENDMENT FILED Loading...
Aug 28, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 26, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 26, 2019 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 26, 2019 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 16, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 19, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 19, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 30, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 11, 2019 ALIE A ASSIGNED TO LIE Loading...
Dec 18, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 17, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 17, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 17, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 12, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 12, 2018 CPRA R PRIORITY ACTION WRITTEN Loading...
Dec 12, 2018 GPRA F PRIORITY ACTION E-MAILED Loading...
Dec 12, 2018 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Sep 7, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 1, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical drug development services; Research and development in the pharmaceutical and biotechnology fields; Medical and scientific research in the field of cancer treatment and diagnosis; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Software as a service (SAAS) services featuring software for precision oncology drug library screening; Product research and development, namely, testing of the newest drugs through high-throughput smart-screening platform to determine the best pharmacological treatments for an individual patient; Pharmacological product research consultation services that will enable others, namely, doctors and clinicians, to select and recommend the appropriate treatment for patients through the use of data obtained through personalized pharmacogenetics, genomics, proteomics and other biological testing
First Use Anywhere: Sep 16, 2019
First Use in Commerce: Sep 16, 2019
Class 044
Medical testing for diagnostic or treatment purposes; Providing cancer screening services; Genetic counseling; Genetic testing for medical purposes; Health care services for treating cancer; Medical analysis services for the diagnosis of cancer; Providing personalized healthcare and medical information in the nature of providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment for patients through the use of data obtained through personalized pharmacogenetics, genomics, proteomics and other biological testing, individual behaviors including medication compliance, exercise, diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis
First Use Anywhere: Sep 16, 2019
First Use in Commerce: Sep 16, 2019

Classification

International Classes
042 044